11/WA/0363 12/NW/0585 13/YH/022 13/EM/0254 GTAC185 14/EM/0001	Study Title A Phase 2 MultiCenter, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Trastuzumab Emtansine (TDM1) (GATSBY) MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	ment Target	31/07/2014	Closed - In Follow	Performance Against Target Target Not Met
11/WA/0363 12/NW/0585 13/YH/022 13/EM/0254 GTAC185 14/EM/0001	A Phase 2 MultiCenter, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Trastuzumab Emtansine (TDM1) (GATSBY) MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	1	31/03/2014 31/07/2014	Closed - Follow Up Complete Closed - In Follow	
11/WA/0363 12/NW/0585 13/YH/022 13/EM/0254 GTAC185 14/EM/0001	Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Trastuzumab Emtansine (TDM1) (GATSBY) MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	2	31/07/2014	Complete Closed - In Follow	Target Not Met
11/WA/0363 12/NW/0585 13/YH/022 13/EM/0254 GTAC185 14/EM/0001	Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Trastuzumab Emtansine (TDM1) (GATSBY) MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	2	31/07/2014	Complete Closed - In Follow	Target Not Met
11/WA/0363 12/NW/0585 13/YH/022 13/EM/0254 GTAC185 14/EM/0001	Leukemia (Ph+ ALL) Trastuzumab Emtansine (TDM1) (GATSBY) MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	2	31/07/2014	Complete Closed - In Follow	Target Not Met
12/NW/0585 13/YH/022 13/EM/0254 GTAC185 14/EM/0001	Trastuzumab Emtansine (TDM1) (GATSBY) MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	2	31/07/2014	Closed - In Follow	Target Not Met
13/YH/022 13/EM/0254 GTAC185 14/EM/0001	MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)				
13/YH/022 13/EM/0254 GTAC185 14/EM/0001	MCRN221 MCI-196-E16 PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)			Up	
13/EM/0254 GTAC185 14/EM/0001	PROMETHEUS CCRN 2232 - PROMETHEUS: Visual impairment due to VEGF driven Macular Oedema (CRFB002G2302)	2	21/07/2014		Target Met
13/EM/0254 GTAC185 14/EM/0001	VEGF driven Macular Oedema (CRFB002G2302)		51/0//2014	Withdrawn	Withdrawn
13/EM/0254 GTAC185 14/EM/0001	VEGF driven Macular Oedema (CRFB002G2302)			Closed - In Follow	
GTAC185 14/EM/0001		3	31/08/2014		Target Met
14/EM/0001			51/00/2014	Closed - In Follow	Turget Wet
14/EM/0001	DDOGTVAC V/F + / CNA CCF in prostate concer	5	21/09/2014		Target Met
	PROSTVAC-V/F +/- GM-CSF in prostate cancer	5	31/08/2014		Target Met
		_		Closed - In Follow	
13/SC/0213	TREND (CRFB002A2411)	5	05/09/2014		Target Met
13/SC/0213				Closed - In Follow	
	ACT IV Study - Protocol CDX110-04	6	30/09/2014		Target Not Met
				Closed - Follow Up	
13/NW/0464	CCRN 2274 (Liver failure)	4	30/09/2014	Complete	Target Not Met
	M12-813: Elagolix in Premenopausal Women with Heavy Menstrual			Closed - In Follow	
	Bleeding Associated with Uterine Fibroids	4	30/09/2014		Target Not Met
	ROCHE PHASE I SINGLE ASCENDING DOSE Study of RO6867461 in	+	,,+	Closed - Follow Up	
	wAMD	3	30/12/2014		Target Mot
13/ NL/U294	עועותאיי	3	50/12/2014		Target Met
10/110 100/100			24/12/22	Closed - Follow Up	
	ABBOTT 880 CCRN 282 (Inactive uveitis)	4	31/12/2014		Target Met
	OCTAVE A3921095: 007: Oral CP690,550 as an Induction Therapy for		1	Closed - Follow Up	
12/LO/0080	Ulcerative Colitis	5	31/12/2014	Complete	Target Not Met
	OCTAVE A3291139: 009: Open- label oral CP690,550 for Treatment of			Closed - In Follow	
12/LO/0082	Ulcerative Colitis	5	31/12/2014	Up	Target Not Met
	MCRN223 MCI-196-E15 Extension Study Evaluating Colestilan	2			Withdrawn
10/11/0011		-	01/12/2011	Closed - Follow Up	
12/11/064	ZEST	4	31/12/2014		Target Met
12/WA/1064	ZE31	4	51/12/2014		Target Met
/ /				Closed - In Follow	
13/EE/0263	MASTER II Trial	20	31/12/2014		Target Met
				Closed - In Follow	
12/EE/0071	CCRN 923 (Ascites)	6	31/05/2015	Up	Target Met
	NCRN371 INO-VATE: B1931022 Inotuzumab in Acute Lymphoblastic			Closed - In Follow	
12/SC/0309	Leukaemia	1	31/01/2015	Up	Target Met
	Intravenous zanamivir versus oral oseltamivir in hospitalised influenza			Closed - Follow Up	
10/H1003/120	(NAI114373 - ZORO)	2	27/02/2015		Target Not Met
	MCRN222 (MCI-196-E14)	1			Withdrawn
	JETREA FIRSTLINE (ALCON) - Assessment of Patients Treated With	-	20,02,2010		
	JETREA® for Vitreomacular Traction	5	06/03/2015	Withdrawn	Withdrawn
14/30/0100		5	00/05/2015		withurawii
				Closed - Follow Up	
13/YH/0136	CCRN 2173 (AI Liver Decompensation)	2	30/03/2015		Target Not Met
			1	Closed - In Follow	
13/NW/0320	MCRN235 (WA28117)	2	31/03/2015	Up	Target Met
	NCRN492 - NEMO-MEK162 vs Dacarzabine in NRAS mutation postive			Closed - In Follow	
13/LO/0720	melanoma patients	2	31/03/2015	Up	Target Not Met
	GO-COLITIS	6			Withdrawn
		1		Closed - In Follow	
14/EE/1001	OTO-104 in Meniere's Disease	5	17/04/2015		Target Met
	OCTAVE A3921096: 008: Oral CP-690, 550 as Maintenance Therapy for		17/04/2015	Closed - Follow Up	I SIGULIVICI
		-	20/04/2015	•	Torgot Not NA
12/LO/0081	Ulcerative Colitis	3	30/04/2015		Target Not Met
			1	Closed - In Follow	
	CCRN - 3308 The DEFLECT III Trial	6			Target Met
14/YH/0048	Apposition V	25	30/04/2015	Withdrawn	Withdrawn
				Closed - In Follow	
	CCRN 771 (Endometriosis-related pain)	6	08/05/2015	Up	Target Not Met
13/WA/0269				Closed - In Follow	
13/WA/0269		1	31/05/2015		Target Met
	NCRN252 - Nilotinib in paediatric Ph+ CML/ALL	· ·	, 00, 2013	Closed - Follow Up	
	NCRN252 - Nilotinib in paediatric Ph+ CML/ALL				L
10/H1308/84	· · · · ·		31/05/2015	Complete	
10/H1308/84 12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	4	31/05/2015	Complete	Target Met
10/H1308/84 12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17 CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric				
10/H1308/84 12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17	4		Withdrawn	Target Met Withdrawn
10/H1308/84 12/SC/0434	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17 CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric				
10/H1308/84 12/SC/0434 14/WM/1228	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17 CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric		31/05/2015	Withdrawn Closed - In Follow	
10/H1308/84 12/SC/0434 14/WM/1228	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17 CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE)	13	31/05/2015	Withdrawn Closed - In Follow	Withdrawn
10/H1308/84 12/SC/0434 14/WM/1228 12/NW/0641	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17 CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE) NCRN442 BRIM 8: Vemurafenib in adjuvant melanoma	13	31/05/2015 15/06/2015	Withdrawn Closed - In Follow Up	Withdrawn Target Met
10/H1308/84 12/SC/0434 14/WM/1228 12/NW/0641	(MCRN194) DPM-CF-204 mannitol in CF aged 6-17 CHIL3846 Abbott Sensor Based Glucose Monitoring System Paediatric Study (BEAGLE)	13 9	31/05/2015 15/06/2015	Withdrawn Closed - In Follow Up Open	Withdrawn Target Met Still open to

Research Ethics		Recruit			
Committee		ment	Recruitment		Performance Against
Reference	Study Title	Target	End Date	Study Status	Target
	An Open-Label, Phase 1, Dose Escalation Study of MLN2480 in Patients				
	with Relapsed or Refractory Solid Tumors Followed by a Dose				Still open to
13/SC/0007	Expansion Phase in Patients With Unresectable Melanoma.	5	31/07/2015	Open	Recruitment
					Still open to
13/SC/0268	CCRN2100 (Cystic fibrosis)	3	31/07/2015	Open	Recruitment
	NCRN561 : The regorafenib in patients with hepatocellular carcinoma				Still open to
13/LO/0150	(RESORCE)	2	01/08/2015	Open	Recruitment
13/SW/0186	EFFECT - Efficacy of Fluticasone/Formoterol in COPD Treatment		31/08/2015	VA (it is a location	14/211
		4		Withdrawn	Withdrawn Still open to
13/YH/0126	GWCA1208 - Study of Sativex in Patients with Recurrent Glioblastoma	4	31/08/2015	Onen	Recruitment
13/EM/0149	15961 GadaCAD1	15		Withdrawn	Withdrawn
	MCRN 2419: KOGNITO (Kuvan®'s effect on the cOGNITion of children				Still open to
13/LO/0945	with phenylketOnuria)	2	30/09/2015	Open	Recruitment
	CANC - 3482 JANUS 1: Ruxolitinib or placebo + Capecitabine in				Still open to
14/SC/1014	pancreatic adenocarcinoma	2	30/09/2015	Open	Recruitment
					Still open to
14/YH/1124	EXTEND (2819MA1002)	3	30/09/2015	Open	Recruitment
					Still open to
14/YH/1263	GLYSURE Study	10	30/09/2015	Open	Recruitment
	MAESTRO: Macitentan in Eisenmenger Syndrome AC-055-305 (CCRN				Still open to
13/LO/0161	2104)	3	01/10/2015		Recruitment
12/10/1202		6	20/10/2015	Closed - In Follow	Torgot Mot
13/LO/1283	MO 28037 - TAMIGA	0	30/10/2015	op	Target Met Still open to
12/NW/0367	MCRN177 (BEL114055)	1	31/10/2015	Onon	Recruitment
12/1007/0307		1	51/10/2013	Open	Still open to
13/LO/0717	CL3-78989-006. EYEGUARD-C study	4	30/11/2015	Onen	Recruitment
13/10/0/1/			50/11/2015	open	Still open to
14/EM/0034	NCRN3025 - GDC-0199 in CLL (GO28667) - MURANO	2	30/11/2015	Open	Recruitment
, ,	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage				Still open to
14/EM/0130	Chemotherapy	2	01/12/2015	Open	Recruitment
					Still open to
13/WS/0304	EVARREST (The Fibrin Pad CV Phase III Study)	10	31/12/2015	Open	Recruitment
					Still open to
13/YH/0201	MCRN2280 Sativex Severe Spasticity (GWSP08258)	6	31/12/2015	Open	Recruitment
12/10/1000			24/42/2045	0	Still open to
13/LO/1608	Study of efficacy and safety of nilotinib in paediatric CML patients	1	31/12/2015	Open	Recruitment Still open to
14/SC/0181	Elagolix in Endometriosis Associated Pain - Extension	1	31/12/2015	Open	Recruitment
14/30/0101	NCRN - 3245 - Betalutin radioimmunotherapy for treatment of		51/12/2015	open	Still open to
14/NI/1037	relapsed CD37+ NHL	1	31/12/2015	Open	Recruitment
					Still open to
14/LO/0036	NCRN2555 - TOWER Study (00103311)	5	31/01/2016	Open	Recruitment
					Still open to
13/WM/0143	Study of Moxetumomab Pasudotox in pALL or LL of B-Cell	1	31/01/2016	Open	Recruitment
					Still open to
14/EM/0215	M12-914 Phase III Veliparib/Placebo + C/P Breast Cancer Study	1	29/02/2016	Open	Recruitment
	ABBOTT 327 CCRN 283 (LT uveitis)		31/03/2016		Still open to
10/H0406/47		8		Open	Recruitment
12/5/4/0004		-	21/02/2010	Open	Still open to
12/SW/0084	LFG316 MFC	5	31/03/2016	Open	Recruitment
14/NI/1075	CHII 3670 (ALX0171-C104)	1	31/03/2016	Open	Still open to Recruitment
1+/ IVI/ 10/3	CHIL3670 (ALX0171-C104)	1 I	51/03/2010	open	Still open to
13/WA/0101	CCRN 2088 (Pneumonia)	6	30/04/2016	Open	Recruitment
14/YH/0007	MCRN2368 UCB PRA Epilepsy Lacosamide SP0969	2		Withdrawn	Withdrawn
	, , , ,	+	,,	Closed - In Follow	
14/NW/0001	CCRN 2979 (Haemophilia A)	2	31/05/2016		Target Met
	AZD9291 v chemotherapy in NSCLC, following EGFR TKI therapy				Still open to
14/EE/1063	(AURA3)	3	31/05/2016	Open	Recruitment
					Still open to
14/WS/0004	CCRN 2825 (Hypercholesterolemia)	10	03/06/2016	Open	Recruitment
	NCRN490: CA184-178 Ipilimumab in children(aged 12<18)with				Still open to
13/EM/0012	malignant melanoma	1	30/06/2016	Open	Recruitment
40/10/07/			20/20/		Still open to
13/LO/0716	CCRN 2159 (Uveitis)	4	30/06/2016	Open	Recruitment
44504243		-	20/06/200	la set i	Still open to
14/SC/1311	MCRN3165 (SD744) Cubist PSI Osteomyelitis	3	30/06/2016	in set up	Recruitment

Research Ethics		Recruit			
Committee		ment	Recruitment		Performance Against
Reference	Study Title		End Date	Study Status	Target
			I		Still open to
15/SC/0054	CheckMate 238 (Nivolumab vs Ipilimumab in Melanoma)	6	30/06/2016	Open	Recruitment
					Still open to
13/NW/0002	CCRN 1073 (Thoracic aortic surgery)	15	31/07/2016	Open	Recruitment
				-	Still open to
14/LO/1617	GLP110933 study Type I DM Study (DRN 3266)	2	14/08/2016	Open	Recruitment
	COAST BAY73-4506/15983: Regorafenib as adjuvant therapy for			-	Still open to
13/NW/0705	resected liver metastases	7	31/08/2016	Open	Recruitment
					Still open to
14/SC/1425	CCRN 2738 (AMD)	7	31/10/2016	Open	Recruitment
					Still open to
11/SC/0173	VIABLE	6	31/12/2016	Open	Recruitment
					Still open to
15/NW/0009	MCRN3127 (20130173)	3	28/02/2017	Open	Recruitment
	MCRN2947 (ALS-8176-503) Developing a new drug to treat infants				Still open to
14/WM/0013	hospitalised with RSV infection	8	30/04/2017	Open	Recruitment
				Closed - In Follow	
11/LO/0923	NCRN259 HERBY - Bevacizumab in paediatric high grade glioma	3	22/08/2017	Up	Target Met
	WA29231- LONG-TERM EXTENSION STUDY TO EVALUATE THE SAFETY				
	AND EFFICACY OF SUBCUTANEOUS TOCILIZUMAB IN PATIENTS WITH				
	POLYARTICULAR-COURSE AND SYSTEMIC JUVENILE IDIOPATHIC				Still open to
14/NE/0122	ARTHRITIS	1	30/09/2017	Open	Recruitment
					Still open to
13/LO/0418	SD560 Pfizer PPHN Sildenafil A1481316 (MCRN228)	2	31/10/2017	Open	Recruitment
	GA29103: PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND,				
	DOUBLE-DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF				
	ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH				
	MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAIVE				Still open to
14/NE/1099	TO TNF INHIBITORS	1	31/12/2017	Open	Recruitment